| Dr Christopher M Lambert, MD | |
|
Two W 52nd Street, Ste 2200, Scottsbluff, NE 69361-0617 | |
| (308) 630-2626 | |
| (308) 630-2636 |
| Full Name | Dr Christopher M Lambert |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 27 Years |
| Location | Two W 52nd Street, Scottsbluff, Nebraska |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1104846070 | NPI | - | NPPES |
| CC5649 | Other | NV | BLUE CROSS BLUE SHIELD |
| 100500527 | Medicaid | NV | |
| 10025925600 | Medicaid | NE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 10506 (Nevada) | Secondary |
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 27417 (Nebraska) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Regional West Medical Center | Scottsbluff, NE | Hospital |
| Box Butte General Hospital | Alliance, NE | Hospital |
| Morrill County Community Hospital | Bridgeport, NE | Hospital |
| Poudre Valley Hospital | Fort collins, CO | Hospital |
| Community Hospital | Torrington, WY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Poudre Valley Medical Group Llc | 9638208549 | 1605 |
News Archive
Tetraphase Pharmaceuticals Inc., a biopharmaceutical company capitalizing on breakthrough synthetic chemistry technology announced today that it will present three (3) posters and deliver a slide presentation on the synthesis and antibacterial activity of analogs from several novel classes of antibiotics to treat drug-resistant infections at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco, CA.
As new genes are linked to breast cancer occurring in families and as genetic testing becomes more important in directing treatment for newly diagnosed patients, a substantial number of those at the highest risk are not getting tested.
Curis, Inc. (NASDAQ: CRIS), a drug development company focused on developing proprietary targeted medicines for cancer treatment, today announced that two publications describing clinical data generated with GDC-0449 were published in the current edition of The New England Journal of Medicine (NEJM).
Innovative new mobile network Audacious has partnered with Boots Hearingcare to collaborate on their shared mission of supporting people living with hearing loss.
ImmunoGen, Inc., a biotechnology company that develops targeted antibody-based anticancer products, today announced the start of clinical testing with SAR566658. Eight compounds are now in the clinic through ImmunoGen's product programs and those of its partners, consistent with Company expectations of as many as 12 such compounds being in the clinic by late 2011 and marked, sustained pipeline growth thereafter.
› Verified 5 days ago
| Entity Name | Poudre Valley Medical Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366763260 PECOS PAC ID: 9638208549 Enrollment ID: O20100817000717 |
News Archive
Tetraphase Pharmaceuticals Inc., a biopharmaceutical company capitalizing on breakthrough synthetic chemistry technology announced today that it will present three (3) posters and deliver a slide presentation on the synthesis and antibacterial activity of analogs from several novel classes of antibiotics to treat drug-resistant infections at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco, CA.
As new genes are linked to breast cancer occurring in families and as genetic testing becomes more important in directing treatment for newly diagnosed patients, a substantial number of those at the highest risk are not getting tested.
Curis, Inc. (NASDAQ: CRIS), a drug development company focused on developing proprietary targeted medicines for cancer treatment, today announced that two publications describing clinical data generated with GDC-0449 were published in the current edition of The New England Journal of Medicine (NEJM).
Innovative new mobile network Audacious has partnered with Boots Hearingcare to collaborate on their shared mission of supporting people living with hearing loss.
ImmunoGen, Inc., a biotechnology company that develops targeted antibody-based anticancer products, today announced the start of clinical testing with SAR566658. Eight compounds are now in the clinic through ImmunoGen's product programs and those of its partners, consistent with Company expectations of as many as 12 such compounds being in the clinic by late 2011 and marked, sustained pipeline growth thereafter.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Christopher M Lambert, MD Two W 52nd Street, Ste 2200, Scottsbluff, NE 69361-0617 Ph: (308) 630-2626 | Dr Christopher M Lambert, MD Two W 52nd Street, Ste 2200, Scottsbluff, NE 69361-0617 Ph: (308) 630-2626 |
News Archive
Tetraphase Pharmaceuticals Inc., a biopharmaceutical company capitalizing on breakthrough synthetic chemistry technology announced today that it will present three (3) posters and deliver a slide presentation on the synthesis and antibacterial activity of analogs from several novel classes of antibiotics to treat drug-resistant infections at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco, CA.
As new genes are linked to breast cancer occurring in families and as genetic testing becomes more important in directing treatment for newly diagnosed patients, a substantial number of those at the highest risk are not getting tested.
Curis, Inc. (NASDAQ: CRIS), a drug development company focused on developing proprietary targeted medicines for cancer treatment, today announced that two publications describing clinical data generated with GDC-0449 were published in the current edition of The New England Journal of Medicine (NEJM).
Innovative new mobile network Audacious has partnered with Boots Hearingcare to collaborate on their shared mission of supporting people living with hearing loss.
ImmunoGen, Inc., a biotechnology company that develops targeted antibody-based anticancer products, today announced the start of clinical testing with SAR566658. Eight compounds are now in the clinic through ImmunoGen's product programs and those of its partners, consistent with Company expectations of as many as 12 such compounds being in the clinic by late 2011 and marked, sustained pipeline growth thereafter.
› Verified 5 days ago
Kelly Jo Coon, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 4021 Avenue B, Scottsbluff, NE 69361 Phone: 308-630-2920 | |
Dr. Vincent Gene Bjorling, M.D. Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 3911 Avenue B, Suite 1110, Scottsbluff, NE 69361 Phone: 308-630-2100 Fax: 308-630-2138 | |
Dr. Jaroslaw P. Aniszewski, M.D. Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 3911 Avenue B, Suite 3400, Scottsbluff, NE 69361 Phone: 308-630-2101 | |
David B Johnson, MD Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 3911 Avenue B, Suite 1100, Scottsbluff, NE 69361 Phone: 308-630-2101 | |
Dr. Brittany R Eirich, MD. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 3911 Ave B Ste #1100, Scottsbluff, NE 69361 Phone: 720-732-3406 Fax: 303-318-2481 | |
Caleb Wilson, Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 4021 Avenue B, Scottsbluff, NE 69361 Phone: 308-635-3711 |